PQR 309

Drug Profile

PQR 309

Alternative Names: PQR-309

Latest Information Update: 31 Mar 2017

Price : $50

At a glance

  • Originator PIQUR Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Lymphoma
  • Phase I/II Breast cancer
  • Phase I Solid tumours
  • Preclinical Brain disorders; Eye disorders; Skin cancer; Skin disorders

Most Recent Events

  • 21 Apr 2017 PIQUR Therapeutics plans a phase II trial for CNS cancer (Second-line therapy or greater, Refractory metastatic disease) in France (NCT03120000)
  • 01 Mar 2017 PIQUR Therapeutics re-initiates enrolment in a phase II trial for Lymphoma (Second-line therapy or greater) in Germany (EudraCT2016-000125-38)
  • 08 Feb 2017 Preclinical trials in Skin cancer and Skin disorders in Switzerland (Topical), before February 2017 (PIQUR Therapeutics website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top